Integrative mendelian randomization and multi-omics analysis reveal a gut microbiota-metabolite-CXCL10 axis in breast cancer.

ABSTRACT: Breast cancer remains the leading cause of cancer morbidity and mortality worldwide, with limited efficacy in advanced breast cancer patients due to tumor heterogeneity and drug resistance. Emerging evidence suggests that the gut microbiota is associated with breast cancer progression through metabolites and immunomodulatory effects. However, mechanistic insights and therapeutic targets combining the gut microbiota and host genetics remain underexplored. In this study, we performed Mendelian randomization (MR) analysis via cis-eQTLs from breast cancer GWASs and druggable gene datasets to identify genes causally associated with breast cancer risk. Differential gene expression analysis was conducted using TCGA data. Gut microbiota-target-metabolite networks were constructed from the gutMGene

SUBMITTER: Qu J 

PROVIDER: S-EPMC12748410 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature